Phase 2 COPD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older.
- People who have a performance status score of 60% or higher on the Karnofsky scale, which means they are able to care for themselves and carry out some normal activities (confirm with trial site).
- People who have been diagnosed with chronic graft-versus-host disease (a condition that can occur after a stem cell or bone marrow transplant) according to standard medical guidelines, and whose treating doctor has determined they need their first systemic (whole-body) treatment for it. A form called "overlap chronic GVHD" is also allowed.
- People who have not had any new immune-suppressing medications added in the 2 weeks before joining the study.
- People who are able to swallow and take oral (by mouth) medications.
- People whose blood counts and organ function meet the required levels — including adequate white blood cells, platelets, red blood cells, liver function, and kidney function (the trial site will assess these through blood tests).
- Women who could become pregnant and men must agree to use appropriate contraception during the study, and men must continue this for 4 months after finishing the study treatment. Anyone who becomes pregnant or suspects pregnancy during the study must inform their treating doctor right away.
- People who are willing and able to understand and sign an informed consent form.
Who may not be able to join:
- People who have previously received systemic (whole-body) immune-suppressing treatment specifically for chronic graft-versus-host disease.
- People with serious or uncontrolled heart problems, including unstable chest pain, a heart attack or stroke within the past 6 months, or severe heart failure (classified as New York Heart Association class III or IV).
- People whose cancer or original disease has come back after their transplant.
- People with active hepatitis B, hepatitis C, or HIV.
- People who have an uncontrolled infection at the time of enrolment.
- People who have had a serious allergic reaction to a medication that is chemically or biologically similar to the study drug (Ruxolitinib).
- People with mental health conditions or personal circumstances that would make it difficult to follow the study requirements.
- Women who are pregnant or breastfeeding, due to potential risks to the baby from the study drug. Breastfeeding would need to be stopped if the study drug is used.
- People with a current or past history of active tuberculosis (TB).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Farhad Khimani, MD, Moffitt Cancer Center
Phone: 813-745-2690
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Treatment Success
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.